TouchIMMUNOLOGY got the chance to catch up with Hans Prenen (University Hospital Antwerp, Edegem, Belgium) around the potential advantages of non-gene edited allogeneic CAR T cell therapy (Clinical Trial Identifier: NCT03692429).
The abstract ‘Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.’ (ABSTRACT NUMBER: 74) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
Questions
- What are the potential advantages of non-gene edited allogeneic CAR T cell therapy? (0:26)
- What does the future hold for non-gene edited allogeneic approaches? (1:54)
Disclosures: Hans Prenen has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
